Patient Information

Direct-acting antivirals: One of several keys to HCV eradication by 2030


 

Can the public health threat posed by the hepatitis C virus (HCV) be eliminated by 2030? Researchers in Italy say it can be done. Important elements of success will include the use of oral direct-acting antivirals and a global commitment to prevention. Earlier this year, the World Health Organization (WHO) announced plans to wipe out HCV worldwide by 2030 using the time between now and 2021 to reduce the number of annual new infections by 70%, and to slash the fatality rate by 60%. Find out what success in meeting the WHO challenge will hinge on by going to Family Practice News: http://www.mdedge.com/familypracticenews/article/114780/gastroenterology/direct-acting-antivirals-one-several-keys-hcv.

Recommended Reading

Analysis yields ‘strong evidence’ for benefit of physical activity in NAFLD
MDedge Family Medicine
Investigational HCV drug combo yields high SVR12 rates in compensated cirrhosis
MDedge Family Medicine
Direct-acting antivirals: One of several keys to HCV eradication by 2030
MDedge Family Medicine
Nonalcoholic fatty liver disease estimated to cost $103 billion annually
MDedge Family Medicine
Vitamin D deficiency linked to hepatitis B infection
MDedge Family Medicine
Study finds clues to fibrosis progression in chronic HCV infection
MDedge Family Medicine
Ombitasvir, paritaprevir, ritonavir, and dasabuvir in CKD patients with HCV
MDedge Family Medicine
VIDEO: Harvoni shows safety, efficacy in adolescents for hepatitis C
MDedge Family Medicine
Hepatitis Outlook: September 2016
MDedge Family Medicine
Frailty stratifies pediatric liver disease severity
MDedge Family Medicine